The device has not been returned for evaluation yet; therefore, the event cause could not be determined.Correspondence has been sent out for the device.Once the device is received and the investigation has been completed, a supplemental report will be submitted.If information is provided in the future, a supplemental report will be issued.
|
Medtronic received report that during the placement of the medtronic flow diverter, there was resistance when the device was advanced, the flow diverter was opened not longer than one third of the length.The flow diverter was placed in a curved angle and was partially collapsed and twisted.This occurred after one attempt to resheath flow diverter and was slight out of the pusher.No patient injury occurred.This event occurred during the treatment of a right internal carotid artery aneurysm.The aneurysm was unruptured, max diameter was 31mm with a neck of 9mm.The distal landing zone was 3.8mm and the proximal was 4.6mm.The anatomy was severe.
|
The pipeline flex was returned without the catheter.The distal and proximal dps restraints were found to be intact.The dps sleeves were found intact with no signs of damage.The distal hypotube and ptfe shrink tubing were found to be intact with no signs of elongation.The distal and proximal ends of the pipeline flex braid were fully opened and no damage.No damages were found with the tip coil, distal marker, re-sheathing marker or with the proximal bumper.No other anomalies were observed.Based on the analysis findings, the pipeline flex was not confirmed to have resistance during delivery and failure to open issues.The root cause could not be determined, as no damage was found with the returned pipeline flex delivery system.The pipeline flex braid was fully opened and not damaged.Since the catheter was not returned; any contribution of the catheter to the issues could not be determined.It is likely that the patient tortuous anatomy may have contributed to the reported issues.There was no device malfunction or non-conformance to specifications identified that led to the reported issues.Per our instructions for use (ifu): ¿begin to deliver the device using a combination of unsheathing the pipeline flex embolization device and pushing delivery wire simultaneously.After the distal end of the pipeline flex embolization device has successfully expanded, deploy the remainder of pipeline flex embolization device by pushing the delivery wire and/or unsheathing the pipeline flex embolization device.Resheathing and/or manipulation of the micro catheter, by locking down the delivery wire and moving both as a system, may facilitate expansion of the pipeline flex embolization device.Discontinue delivery of the device if high force or excessive friction is encountered.Identify the cause of the resistance and remove device and microcatheter simultaneously.Advancement of the ped against resistance may result in device damage or patient injury.Never advance or withdraw an intralumenal device against resistance until the cause of resistance is determined by fluoroscopy.If the cause cannot be determined, withdraw the catheter.Movement of the micro catheter against resistance may result in damage to the micro catheter, or the vessel.Do not use in patients in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment, due to conditions such as severe intracranial vessel tortuosity or stenosis.¿ medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|